NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Kainova Therapeutics

Kainova Therapeutics

Private
MontrealHealthcare & Life Scienceshttps://www.kainovatx.com/en/

Last Round

Series B

Feb 10, 2026

Total Funding Raised

$72.31M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Kainova Therapeutics is a clinical-stage biopharmaceutical company that develops G protein-coupled receptor (GPCR)-modulating therapies for immuno-oncology and inflammation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalGPCRG protein-coupled receptorsimmuno-oncologydrug discoverymonoclonal antibodysmall moleculeinflammatory diseaseclinical-stage biotechdrug licensingsolid tumorbiotech startupdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kainova Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Kainova Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Kainova Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BFeb 10, 2026
Series AMay 10, 2022
GrantJan 27, 2022
DebtJan 13, 2020
VC RoundMay 28, 2019
VC Round
Jul 17, 2012

Key People

Founding team and executive leadership

Stanislas MALMEZAT

Chief Financial Officer

Executive Team

Kainova Therapeutics Investors

Notable investors and investment history

Kainova Therapeutics investors
InvestorRounds
Investissement QuébecSeries B
Idinvest PartnersVC Round
IP GroupVC Round
CTI Life Sciences FundSeries B, Series A
Andera PartnersVC Round
Agence Nationale de la RechercheGrant
3B FUTURE Health FundSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 17, 2026

    Monthly visitors grew 38% MoM, reaching 1.2K.

  • May 16, 2026

    Grew 21% QoQ, from 38 to 46 employees.

Kainova Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kainova Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kainova Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMontreal
Employee Range46
Year Founded2008
Last FundingFeb 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.